|
Aug 25
|
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
|
|
Aug 25
|
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
|
Aug 24
|
AARP to join US government in two more lawsuits over Medicare drug pricing negotiations
|
|
Aug 24
|
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
|
|
Aug 24
|
The Zacks Analyst Blog Highlights Merck, Philip Morris, Qualcomm, CVS Health and Chubb
|
|
Aug 23
|
Top Stock Reports for Merck, Philip Morris & QUALCOMM
|
|
Aug 16
|
Merck Employee Talks Pride, Pediatrics and Parenting
|
|
Aug 15
|
Conservative Stock Portfolio: 10 Best Stocks To Buy
|
|
Aug 15
|
15 Worst Performing Blue Chip Stocks in 2023
|
|
Aug 15
|
Get In on This Skin Disease Drug Before Big Pharma Does
|
|
Aug 11
|
Buy Merck (MRK) Stock Now to Ride a Wave Higher in Healthcare
|
|
Aug 10
|
The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake
|
|
Aug 8
|
Merck Is Harnessing Innovation To Reach Indigenous Communities
|
|
Aug 7
|
Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
|
|
Aug 4
|
Q2 2023 Moderna Inc Earnings Call
|
|
Aug 3
|
U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
|
|
Aug 1
|
Pfizer reports mixed quarterly results on uncertain COVID outlook
|
|
Aug 1
|
Merck upgrades guidance on stronger 2023 outlook as COVID business declines
|
|
Aug 1
|
Merck (MRK) Q2 2023 Earnings Call Transcript
|
|
Aug 1
|
Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View
|